The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Treatment strategies for Leber hereditary optic neuropathy
Open accessAbstract
Purpose of review: Leber hereditary optic neuropathy (LHON) is the most common primary mitochondrial DNA (mtDNA) disorder in the population and it carries a poor visual prognosis. In this article, we review the development of treatment strategies for LHON, the evidence base and the areas of unmet clinical need. Recent findings: There is accumulating evidence that increasing mitochondrial biogenesis could be an effective strategy for protecting retinal ganglion cells in LHON. A number of clinical trials are currently investigating the efficacy of viral-based gene therapy for patients harbouring the m.11778G>A mtDNA mutation. For female LHON carriers of childbearing age, mitochondrial replacement therapy is being offered to prevent the maternal transmission of pathogenic mtDNA mutations. Summary: Although disease-modifying treatment options remain limited, a better understanding of the underlying disease mechanisms in LHON is paving the way for complementary neuroprotective and gene therapeutic strategies for this mitochondrial optic nerve disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Current treatments for LHON remain inadequate.8 Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances, 9,10 but its benefits are limited.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673
Huang, C.-F., Chang, Y., Hsueh, Y., Huang, C.-W., Wang, D.-H., Huang, T.-C., Wu, Y.-T., Su, F., Hughes, M. W., Chuong, C., et al. (2016) · Scientific Reports · doi:10.1038/srep31257 · Cited by 941
Mitochondrial optic neuropathies—Disease mechanisms and therapeutic strategies
Yu-Wai-Man, P., Griffiths, P. G., & Chinnery, P. F. (2011) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2010.11.002 · Cited by 633
Self-citationVitamin B 3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice
Williams, P. A., Harder, J. M., Foxworth, N. E., Cochran, K. E., Philip, V. M., Porciatti, V., Smithies, O., & John, S. W. M. (2017) · Science · doi:10.1126/science.aal0092 · Cited by 617
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Self-citationThe Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Yu‐Wai‐Man, P., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 485
Self-citationEells, J. T., Wong‐Riley, M. T. T., VerHoeve, J. N., Henry, M. M., Buchmann, E. V., Kane, M. P., Gould, L. J., Das, R., Jett, M., & Hodgson, B. D. (2004) · Mitochondrion · doi:10.1016/j.mito.2004.07.033 · Cited by 477
Live birth derived from oocyte spindle transfer to prevent mitochondrial disease
Zhang, J., Liu, H., Luo, S., Lu, Z., Chávez-Badiola, A., Liu, Z., Yang, M., Merhi, Z. O., Silber, S. J., Munné, S., et al. (2017) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2017.01.013 · Cited by 368
Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease
Hyslop, L., Blakeley, P., Craven, L., Richardson, J. M., Fogarty, N. M. E., Fragouli, E., Lamb, M., Wamaitha, S. E., Prathalingam, N., Zhang, Q., et al. (2016) · Nature · doi:10.1038/nature18303 · Cited by 350
Giordano, C., Iommarini, L., Giordano, L., Maresca, A., Pisano, A., Valentino, M. L., Caporali, L., Liguori, R., Deceglie, S., Roberti, M., et al. (2013) · Brain · doi:10.1093/brain/awt343 · Cited by 282
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz7423 · Cited by 232
Self-citationNewman, N. J., Yu-Wai-Man, P., Carelli, V., Moster, M. L., Biousse, V., Vignal-Clermont, C., Sergott, R. C., Klopstock, T., Sadun, A. A., Barboni, P., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.12.012 · Cited by 168
“Current treatments for LHON remain inadequate.(8) Idebenone (Raxone, Santhera GmbH) was granted market authorization by the European Medicines Agency (EMA) for the treatment of LHON under exceptional circumstances,(9,10) but its benefits are limited.”
BackgroundSelf-citationNewman, N. J., Carelli, V., Taiel, M., & Yu-Wai-Man, P. (2020) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001045 · Cited by 111
Self-citationMoster, M. L., Sergott, R. C., Newman, N. J., Yu-Wai-Man, P., Carelli, V., Bryan, M. S., Smits, G., Biousse, V., Vignal-Clermont, C., Klopstock, T., et al. (2021) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000001316 · Cited by 7
Self-citation
Metadata
- Authors
- Jurkute, N., Harvey, J., & Yu-Wai-Man, P.
- Affiliations
- NIHR Biomedical Research Centre at Moorfields Eye Hospital and UCL Institute of Ophthalmology
- NIHR Moorfields Biomedical Research Centre (GB)
- ORCID
- Harvey, Joshua
- Venue
- Current Opinion in Neurology
- Published
- 2019-02
- Volume
- 32
- Issue
- 1
- Pages
- 99-104
- ISSN
- 1350-7540 (ISSN-L)
- 1473-6551
- OpenAlex
- W2905060112
- Cited by
- 38
- References
- 50
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 3 · 2023: 1 · 2022: 6 · 2021: 9 · 2020: 9 · 2019: 6
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- green
- discovery.ucl.ac.uk
- Locations
- Current Opinion in Neurology (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- Leber's hereditary optic neuropathy, mitochondrial DNA mutations, m.11778G>A mutation, mitochondrial biogenesis, gene therapy, mitochondrial replacement therapy, neuroprotection, disease-modifying therapy
- MeSH terms
- DNA, Mitochondrial, Humans, Mutation, Genetic Therapy, Optic Atrophy, Hereditary, Leber
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
